GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Tellgen Corp (SZSE:300642) » Definitions » EV-to-Revenue

Tellgen (SZSE:300642) EV-to-Revenue : 2.86 (As of Jun. 24, 2024)


View and export this data going back to 2017. Start your Free Trial

What is Tellgen EV-to-Revenue?

EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Tellgen's enterprise value is ¥1,470.3 Mil. Tellgen's Revenue for the trailing twelve months (TTM) ended in Mar. 2024 was ¥514.0 Mil. Therefore, Tellgen's EV-to-Revenue for today is 2.86.

The historical rank and industry rank for Tellgen's EV-to-Revenue or its related term are showing as below:

SZSE:300642' s EV-to-Revenue Range Over the Past 10 Years
Min: 2.72   Med: 8.34   Max: 23.3
Current: 2.86

During the past 12 years, the highest EV-to-Revenue of Tellgen was 23.30. The lowest was 2.72. And the median was 8.34.

SZSE:300642's EV-to-Revenue is ranked better than
52.54% of 826 companies
in the Medical Devices & Instruments industry
Industry Median: 3.02 vs SZSE:300642: 2.86

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

As of today (2024-06-24), Tellgen's stock price is ¥11.22. Tellgen's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2024 was ¥3.15. Therefore, Tellgen's PS Ratio for today is 3.56.


Tellgen EV-to-Revenue Historical Data

The historical data trend for Tellgen's EV-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Tellgen EV-to-Revenue Chart

Tellgen Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 7.03 9.54 7.27 4.10 4.46

Tellgen Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
EV-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.87 4.20 4.50 4.46 3.56

Competitive Comparison of Tellgen's EV-to-Revenue

For the Medical Devices subindustry, Tellgen's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Tellgen's EV-to-Revenue Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Tellgen's EV-to-Revenue distribution charts can be found below:

* The bar in red indicates where Tellgen's EV-to-Revenue falls into.



Tellgen EV-to-Revenue Calculation

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

Tellgen's EV-to-Revenue for today is calculated as:

EV-to-Revenue=Enterprise Value (Today)/Revenue (TTM)
=1470.255/514.037
=2.86

Tellgen's current Enterprise Value is ¥1,470.3 Mil.
Tellgen's Revenue for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥514.0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Tellgen  (SZSE:300642) EV-to-Revenue Explanation

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

Tellgen's PS Ratiofor today is calculated as:

PS Ratio=Share Price (Today)/Revenue per Share (TTM)
=11.22/3.152
=3.56

Tellgen's share price for today is ¥11.22.
Tellgen's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥3.15.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Tellgen EV-to-Revenue Related Terms

Thank you for viewing the detailed overview of Tellgen's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Tellgen (SZSE:300642) Business Description

Traded in Other Exchanges
N/A
Address
No. 115, Lane 572, Bibo Road, Building 1, Zhangjiang Hi-Tech Park, China (Shanghai) Pilot Free Trade Zone, Shanghai, CHN, 201203
Tellgen Corp manufactures and distributes in vitro diagnostic devices for detection of tumor. Its products include tumor marker, human papillomavirus, real time PCR, DNA methylation, autoimmune antibody, infectious disease and others. The company has developed products in the fields of tumor detection, cervical cancer screening, DNA methylation detection, male infertility and prenatal and postnatal care. Its products include tumor marker series products, human papillomavirus series products, Y chromosome microdeletion detection products, real time PCR, autoimmune antibody, and others.
Executives
Zhou Ai Guo Directors, executives
Chen Si Han Securities Affairs Representative

Tellgen (SZSE:300642) Headlines

No Headlines